Longeveron (NasdaqCM:LGVN) - Share price, News & Analysis

LGVN fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

LGVN Stock Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.

Risk Analysis

Earnings are forecast to decline by an average of 22.9% per year for the next 3 years

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months

+ 2 more risks

Longeveron Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Longeveron
Historical stock prices
Current Share Price	US$6.79
52 Week High	US$45.00
52 Week Low	US$2.84
Beta	0
1 Month Change	-13.50%
3 Month Change	0.74%
1 Year Change	-13.50%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-8.37%

Shareholder Returns

	LGVN	US Biotechs	US Market
7D	12.8%	10.3%	6.6%
1Y	-13.5%	-24.4%	-18.5%

Return vs Industry: LGVN exceeded the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: LGVN exceeded the US Market which returned -20.5% over the past year.

Price Volatility

Is LGVN's price volatile compared to industry and market?
LGVN volatility
LGVN Average Weekly Movement	34.0%
Biotechs Industry Average Movement	13.0%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: LGVN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 34% a week.

Volatility Over Time: LGVN's weekly volatility has decreased from 45% to 34% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	19	Chris Min	https://www.longeveron.com

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

Longeveron Fundamentals Summary

How do Longeveron's earnings and revenue compare to its market cap?
LGVN fundamental statistics
Market Cap	US$142.17m
Earnings (TTM)	-US$17.44m
Revenue (TTM)	US$1.30m

109.4x

P/S Ratio

-8.1x

P/E Ratio

Is LGVN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
LGVN income statement (TTM)
Revenue	US$1.30m
Cost of Revenue	US$559.00k
Gross Profit	US$741.00k
Other Expenses	US$18.19m
Earnings	-US$17.44m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.83
Gross Margin	57.00%
Net Profit Margin	-1,341.85%
Debt/Equity Ratio	0%

How did LGVN perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is LGVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LGVN?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for LGVN. This is calculated by dividing LGVN's market cap by their current preferred multiple.
What is LGVN's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$142.17m

LGVN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	88.1x
Enterprise Value/EBITDA	-7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does LGVN's PB Ratio compare to its peers?

LGVN PB Ratio vs Peers

The above table shows the PB ratio for LGVN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	6.7x

Price-To-Book vs Peers: LGVN is good value based on its Price-To-Book Ratio (4.1x) compared to the peer average (6.7x).

Price to Earnings Ratio vs Industry

How does LGVN's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Book vs Industry: LGVN is expensive based on its Price-To-Book Ratio (4.1x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is LGVN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LGVN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LGVN's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of LGVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LGVN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LGVN's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LGVN's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Longeveron forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-22.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LGVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LGVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LGVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LGVN's revenue is expected to decline over the next 3 years (-45.3% per year).

High Growth Revenue: LGVN's revenue is forecast to decline over the next 3 years (-45.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LGVN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Longeveron performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-46.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LGVN is currently unprofitable.

Growing Profit Margin: LGVN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: LGVN is unprofitable, and losses have increased over the past 5 years at a rate of 46.3% per year.

Accelerating Growth: Unable to compare LGVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LGVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: LGVN has a negative Return on Equity (-50.85%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Longeveron's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LGVN's short term assets ($31.9M) exceed its short term liabilities ($2.4M).

Long Term Liabilities: LGVN's short term assets ($31.9M) exceed its long term liabilities ($2.5M).

Debt to Equity History and Analysis

Debt Level: LGVN is debt free.

Reducing Debt: LGVN had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LGVN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LGVN has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 39% each year.

Discover healthy companies

Dividend

What is Longeveron current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LGVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LGVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LGVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LGVN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LGVN has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure

CEO

Chris Min (54 yo)

no data

Tenure

Dr. Kwan-Hong Min, also known as Christopher & Chris, MD, PhD, serves as Chief Medical Officer of Longeveron Inc. from April 04, 2022 and also serves as its Interim Chief Executive Officer since June 01, 2...

Board Members

Experienced Board: LGVN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: LGVN insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/24 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31